These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 19538431)

  • 1. Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura.
    Knöbl P; Jilma B; Gilbert JC; Hutabarat RM; Wagner PG; Jilma-Stohlawetz P
    Transfusion; 2009 Oct; 49(10):2181-5. PubMed ID: 19538431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
    Mayr FB; Knöbl P; Jilma B; Siller-Matula JM; Wagner PG; Schaub RG; Gilbert JC; Jilma-Stohlawetz P
    Transfusion; 2010 May; 50(5):1079-87. PubMed ID: 20070617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
    Jilma-Stohlawetz P; Gorczyca ME; Jilma B; Siller-Matula J; Gilbert JC; Knöbl P
    Thromb Haemost; 2011 Mar; 105(3):545-52. PubMed ID: 21174003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
    Jilma-Stohlawetz P; Gilbert JC; Gorczyca ME; Knöbl P; Jilma B
    Thromb Haemost; 2011 Sep; 106(3):539-47. PubMed ID: 21833442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.
    Spiel AO; Mayr FB; Ladani N; Wagner PG; Schaub RG; Gilbert JC; Jilma B
    Platelets; 2009 Aug; 20(5):334-40. PubMed ID: 19637097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
    Jilma B; Paulinska P; Jilma-Stohlawetz P; Gilbert JC; Hutabarat R; Knöbl P
    Thromb Haemost; 2010 Sep; 104(3):563-70. PubMed ID: 20589313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
    Gilbert JC; DeFeo-Fraulini T; Hutabarat RM; Horvath CJ; Merlino PG; Marsh HN; Healy JM; Boufakhreddine S; Holohan TV; Schaub RG
    Circulation; 2007 Dec; 116(23):2678-86. PubMed ID: 18025536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.
    Jilma-Stohlawetz P; Knöbl P; Gilbert JC; Jilma B
    Thromb Haemost; 2012 Aug; 108(2):284-90. PubMed ID: 22740102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of splenectomy on von Willebrand factor multimeric structure in thrombotic thrombocytopenic purpura refractory to plasma exchange.
    Pereira A; Monteagudo J; Bono A; Lopez-Guillermo A; Ordinas A
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):783-6. PubMed ID: 8292728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The changes in von Willebrand factor multimer in a course of thrombotic thrombocytopenic purpura].
    Saitoh M; Wada H; Tanigawa M; Tamaki S; Masuya M; Minami N; Deguchi K; Shirakawa S; Tatewaki W; Takahashi H
    Rinsho Ketsueki; 1991 Sep; 32(9):1006-8. PubMed ID: 1942536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
    Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
    Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Thrombotic thrombocytopenic purpura which was effectively treated by plasma exchange therapy--involvement of vWF and endothelial cell injury].
    Tanaka H; Kusumi S; Takemoto M; Maehama S; Fujimura K; Kuramoto A; Ninomiya M; Morio K; Okuhara T
    Rinsho Ketsueki; 1989 Dec; 30(12):2205-9. PubMed ID: 2621804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.
    Hollifield AL; Arnall JR; Moore DC
    Am J Health Syst Pharm; 2020 Jul; 77(15):1201-1207. PubMed ID: 32588878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura.
    Reddy PS; Deauna-Limayo D; Cook JD; Ganguly SS; Blecke C; Bodensteiner DC; Skikne BS; Sahud MA
    Ann Hematol; 2005 Apr; 84(4):232-5. PubMed ID: 15517266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent.
    Cosmi B
    Curr Opin Mol Ther; 2009 Jun; 11(3):322-8. PubMed ID: 19479665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Multimeric composition of von Willebrand factor in thrombotic thrombocytopenic purpura. Japanese TTP Study Group].
    Tatewaki W
    Nihon Rinsho; 1993 Jan; 51(1):146-50. PubMed ID: 8433508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Refractory thrombotic thrombocytopenic purpura: successful treatment by plasmapheresis with plasma cryosupernatant.
    Molinari E; Costamagna L; Perotti C; Isernia P; Pagani A; Salvaneschi L
    Haematologica; 1993; 78(6):389-92. PubMed ID: 8175033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk.
    Bae ON
    Arch Pharm Res; 2012 Oct; 35(10):1693-9. PubMed ID: 23139119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006.
    Nguyen L; Li X; Duvall D; Terrell DR; Vesely SK; George JN
    Transfusion; 2008 Feb; 48(2):349-57. PubMed ID: 18028271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thrombotic thrombocytopenic purpura--a syndrome caused by multiple pathogenetic mechanisms.
    Lian EC
    Invest Clin; 2001 May; 42 Suppl 1():75-86. PubMed ID: 11416985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.